Latest Developments in Asia Pacific Multiple Hereditary Exostosis Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Asia Pacific Multiple Hereditary Exostosis Market

  • Pharmaceutical
  • Published Report
  • Oct 2024
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 244
  • No of Figures: 43

  • In January 2023, Ipsen entered into acquisition of Albireo, enhancing its rare disease portfolio with Bylvay (odevixibat), the first approved treatment for progressive familial intrahepatic cholestasis. This strategic move aims to accelerate growth in rare pediatric liver diseases, bolstering Ipsen’s market presence and expanding treatment options for underserved patients.

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 PIPELINE ANALYSIS - OBSERVATORY DATA

4.4 EPIDEMIOLOGY

5 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: REGULATIONS

5.1 REGULATION IN UNITED STATES: U.S. FOOD AND DRUG ADMINISTRATION (FDA)

5.1.1 REGULATION IN EUROPE: EUROPEAN MEDICINES AGENCY (EMA)

5.2 REGULATION IN ASIA-PACIFIC (JAPAN): PHARMACEUTICAL AND MEDICAL DEVICES AGENCY (PMDA)

5.3 MEDICAL DEVICE STANDARDS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF GENETIC DISORDERS

6.1.2 GROWING PEDIATRIC POPULATION

6.1.3 DEVELOPMENT OF NOVEL THERAPIES

6.2 RESTRAINTS

6.2.1 HIGH COST OF ADVANCED THERAPIES

6.2.2 LIMITED AVAILABILITY OF THERAPIES

6.3 OPPORTUNITIES

6.3.1 INCREASE IN PATIENT CARE AND SUPPORT SYSTEMS

6.3.2 INCREASE IN THE NUMBER OF COLLABORATIONS AND PARTNERSHIPS

6.4 CHALLENGES

6.4.1 LIMITED AWARENESS ABOUT THE DISORDER

6.4.2 LACK OF DRUG APPROVALS ASSOCIATED WITH THE DISORDER

7 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE

7.1 OVERVIEW

7.2 SESSILE

7.3 PEDUNCULATED

8 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT

8.1 OVERVIEW

8.2 SURGERY

8.2.1 REMOVE THE TUMOR

8.2.2 LENGTHEN LIMBS

8.3 MEDICATION

8.3.1 HOSPITAL PHARMACIES

8.3.2 DRUGS STORES AND RETAIL PHARMACIES

8.3.3 ONLINE PHARMACIES

8.4 OTHERS

9 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS

9.1 OVERVIEW

9.2 X-RAY

9.2.1 SESSILE

9.2.2 PEDUNCULATED

9.3 COMPUTED TOMOGRAPHY (CT) SCAN

9.3.1 SESSILE

9.3.2 PEDUNCULATED

9.4 MAGNETIC RESONANCE IMAGING (MRI)

9.4.1 SESSILE

9.4.2 PEDUNCULATED

9.5 GENETIC TESTS

9.5.1 SESSILE

9.5.2 PEDUNCULATED

9.6 OTHERS

9.6.1 SESSILE

9.6.2 PEDUNCULATED

10 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE

10.1 OVERVIEW

10.2 LEGS

10.3 ARMS

10.4 SHOULDERS

10.5 PELVIS

10.6 FINGERS

10.7 TOES

11 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP

11.1 OVERVIEW

11.2 PEDIATRIC

11.3 ADULT

12 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITAL

12.2.1 PRIVATE

12.2.2 GOVERNMENT

12.3 SPECIALTY CLINICS

12.4 AMBULATORY SURGICAL CENTERS

12.5 OTHERS

13 ASIA-PACIFIC MULTIPLE HEREDITY EXOSTOSIS MARKET, BY REGION

13.1 ASIA-PACIFIC

13.1.1 CHINA

13.1.2 JAPAN

13.1.3 INDIA

13.1.4 AUSTRALIA

13.1.5 SOUTH KOREA

13.1.6 INDONESIA

13.1.7 NEW ZEALAND

13.1.8 MALAYSIA

13.1.9 THAILAND

13.1.10 TAIWAN

13.1.11 SINGAPORE

13.1.12 PHILIPPINES

13.1.13 VIETNAM

13.1.14 REST OF ASIA-PACIFIC

14 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 BAYERS AG

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT UPDATES

16.2 HALEON GROUP OF COMPANIES

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 BASF

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT UPDATES

16.4 VIATRIS INC.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT UPDATES

16.5 ACTIZAPHARMA

16.5.1 COMPANY SNAPSHOT

16.5.2 PRODUCT PORTFOLIO

16.5.3 RECENT UPDATES

16.6 ADVACARE PHARMA

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT UPDATES

16.7 AUROBINDO PHARMA

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT TABLETS

16.8 HALEON GROUP OF COMPANIES

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT UPDATES

16.9 IPSEN BIOPHARMACEUTICALS, INC.

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT UPDATES

16.1 MALLINCKRODT

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT UPDATES

16.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT UPDATES

16.12 TAJ PHARMACEUTICALS LIMITED

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT UPDATES

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 PIPELINE ANALYSIS - OBSERVATORY DATA

TABLE 2 PIPELINE ANALYSIS - INTERVENTIONAL DATA

TABLE 3 SALES DATA - 2024

TABLE 4 SALES DATA - 2023

TABLE 5 SALES DATA - 2022

TABLE 6 SALES DATA - 2021

TABLE 7 SALES DATA - 2020

TABLE 8 SALES DATA - 2019

TABLE 9 SALES DATA - 2018

TABLE 10 COST OF PALOVAROTENE

TABLE 11 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC SESSILE IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC PEDUNCULATED IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 18 ASIA-PACIFIC MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC LEGS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC ARMS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC SHOULDERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC PELVIS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC FINGERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC TOES IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC PEDIATRIC IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC ADULT IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC SPECIALTY CLINICS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 59 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 61 ASIA-PACIFIC HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 62 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 64 CHINA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 CHINA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 66 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 67 CHINA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 68 CHINA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 69 CHINA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 70 CHINA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 71 CHINA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 72 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 73 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 74 CHINA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 75 CHINA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 77 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 78 JAPAN SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 79 JAPAN MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 80 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 81 JAPAN X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 82 JAPAN COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 JAPAN MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 JAPAN GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 JAPAN OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 86 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 87 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 88 JAPAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 89 JAPAN HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 92 INDIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 93 INDIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 94 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 95 INDIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 96 INDIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 97 INDIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 98 INDIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 99 INDIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 100 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 101 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 102 INDIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 103 INDIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 104 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 106 AUSTRALIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 107 AUSTRALIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 108 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 109 AUSTRALIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 110 AUSTRALIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 AUSTRALIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 112 AUSTRALIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 113 AUSTRALIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 114 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 115 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 116 AUSTRALIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 117 AUSTRALIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 118 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 119 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 120 SOUTH KOREA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 121 SOUTH KOREA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 122 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 123 SOUTH KOREA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 124 SOUTH KOREA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 125 SOUTH KOREA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 126 SOUTH KOREA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 127 SOUTH KOREA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 128 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 129 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 130 SOUTH KOREA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 131 SOUTH KOREA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 132 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 134 INDONESIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 INDONESIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 136 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 137 INDONESIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 138 INDONESIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 139 INDONESIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 140 INDONESIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 141 INDONESIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 142 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 143 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 144 INDONESIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 145 INDONESIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 146 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 147 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 148 NEW ZEALAND SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 149 NEW ZEALAND MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 150 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 151 NEW ZEALAND X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 152 NEW ZEALAND COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 NEW ZEALAND MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 154 NEW ZEALAND GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 155 NEW ZEALAND OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 156 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 157 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 158 NEW ZEALAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 159 NEW ZEALAND HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 160 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 161 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 162 MALAYSIA SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 163 MALAYSIA MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 164 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 165 MALAYSIA X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 166 MALAYSIA COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 167 MALAYSIA MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 168 MALAYSIA GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 169 MALAYSIA OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 170 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 171 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 172 MALAYSIA MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 173 MALAYSIA HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 174 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 175 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 176 THAILAND SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 177 THAILAND MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 178 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 179 THAILAND X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 180 THAILAND COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 181 THAILAND MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 182 THAILAND GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 183 THAILAND OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 184 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 185 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 186 THAILAND MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 187 THAILAND HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 188 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 189 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 190 TAIWAN SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 191 TAIWAN MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 192 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 193 TAIWAN X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 194 TAIWAN COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 TAIWAN MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 196 TAIWAN GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 197 TAIWAN OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 198 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 199 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 200 TAIWAN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 201 TAIWAN HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 202 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 203 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 204 SINGAPORE SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 SINGAPORE MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 206 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 207 SINGAPORE X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 208 SINGAPORE COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 209 SINGAPORE MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 210 SINGAPORE GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 211 SINGAPORE OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 212 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 213 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 214 SINGAPORE MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 215 SINGAPORE HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 216 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 218 PHILIPPINES SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 PHILIPPINES MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 220 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 221 PHILIPPINES X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 222 PHILIPPINES COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 223 PHILIPPINES MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 224 PHILIPPINES GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 225 PHILIPPINES OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 226 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 227 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 228 PHILIPPINES MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 229 PHILIPPINES HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 230 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 231 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)

TABLE 232 VIETNAM SURGERY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 233 VIETNAM MEDICATION IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 234 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY DIAGNOSIS, 2022-2031 (USD THOUSAND)

TABLE 235 VIETNAM X-RAY IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 236 VIETNAM COMPUTED TOMOGRAPHY (CT) SCAN IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 VIETNAM MAGNETIC RESONANCE IMAGING (MRI) IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 238 VIETNAM GENETIC TESTS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 239 VIETNAM OTHERS IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 240 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY SITE, 2022-2031 (USD THOUSAND)

TABLE 241 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)

TABLE 242 VIETNAM MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 243 VIETNAM HOSPITAL IN MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 REST OF ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

List of Figure

FIGURE 1 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 PRODUCT LIFELINE CURVE

FIGURE 9 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: DBMR MARKET POSITION GRID

FIGURE 10 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: SEGMENTATION

FIGURE 12 EXECUTIVE SUMMARY

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC MULTIPLE HEREDITY EXOSTOSIS MARKET, BY TYPE

FIGURE 15 RISING PREVALENCE OF GENETIC DISORDERS IS DRIVING THE GROWTH OF THE ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET FROM 2024 TO 2031

FIGURE 16 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET IN 2024 AND 2031

FIGURE 17 MARKET OVERVIEW

FIGURE 18 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2023

FIGURE 19 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, 2024-2031 (USD THOUSAND)

FIGURE 20 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 21 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2023

FIGURE 23 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)

FIGURE 24 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, CAGR (2024-2031)

FIGURE 25 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 26 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2023

FIGURE 27 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, 2024-2031 (USD THOUSAND)

FIGURE 28 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, CAGR (2024-2031)

FIGURE 29 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY DIAGNOSIS, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2023

FIGURE 31 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, 2024-2031 (USD THOUSAND)

FIGURE 32 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, CAGR (2024-2031)

FIGURE 33 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY SITE, LIFELINE CURVE

FIGURE 34 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2023

FIGURE 35 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)

FIGURE 36 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, CAGR (2024-2031)

FIGURE 37 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 38 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2023

FIGURE 39 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 40 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, CAGR (2024-2031)

FIGURE 41 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 ASIA-PACIFIC MULTIPLE HEREDITY EXOSTOSIS MARKET: SNAPSHOT (2023)

FIGURE 43 ASIA-PACIFIC MULTIPLE HEREDITARY EXOSTOSIS MARKET: COMPANY SHARE 2023 (%)

Frequently Asked Questions

The market is segmented based on Asia-Pacific Multiple Hereditary Exostosis Market Segmentation, By Type (Sessile and Pedunculated), Treatment (Surgery, Medication, and Others), Diagnosis (X-ray, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Genetic Tests, and Others), Site (Legs, Arms, Shoulders, Pelvis, Fingers, and Toes), Age Group (Pediatric and Adult), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others) - Industry Trends and Forecast to 2031 .
The Asia Pacific Multiple Hereditary Exostosis Market size was valued at USD 21.86 USD Million in 2023.
The Asia Pacific Multiple Hereditary Exostosis Market is projected to grow at a CAGR of 4.8% during the forecast period of 2024 to 2031.
The market report covers data from the Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Taiwan, Vietnam, New Zealand, Australia, and Rest of Asia-Pacific.